A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications

Main inclusion criteria are: * Men or women ≥ 18 years old at the time of signing the ICF, * Patient with a CRC, epithelial ovarian cell or fallopian tube carcinoma, urothelial carcinoma, TNBC, pancreatic cancer, AML/MDS or MM, * Disease must be measurable according to the corresponding guidelines, * Patient with an ECOG performance status 0 or 1, and AML patients with anemia resulting in an ECOG performance status of 2, * Patient with adequate bone marrow reserve, hepatic and renal functions. * Patients must have sufficient pulmonary functions with a Forced Expiratory Volume in the first second (FEV-1)/Forced Vital Capacity (FVC) ≥ 0.7 with FEV-1 ≥ 50% predicted. Main exclusion criteria are: * Patient with a tumor metastasis in the central nervous system, * Patients who have received another cancer therapy within 2 weeks before the planned day for the apheresis (except hydroxyurea for AML patients), * Patients who receive or are planned to receive any other investigational product within the 3 weeks before the planned day for the first NKR-2 administration (except hydroxyurea for AML patients), * Patient is under systemic immunosuppressive drugs, unless specific cases authorized per protocol, * Patients who have received other cell therapies, * Patients who underwent major surgery within 4 weeks before the planned day for the first NKR-2 administration. * Patient cannot present with history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, …